AstraZeneca’s (AZN) “Buy” Rating Reiterated at Jefferies Financial Group

Jefferies Financial Group reissued their buy rating on shares of AstraZeneca (LON:AZN) in a research note issued to investors on Wednesday,Digital Look reports. The brokerage currently has a £175 price target on the biopharmaceutical company’s stock.

Several other analysts have also issued reports on the company. Berenberg Bank restated a “buy” rating and issued a £175 price objective on shares of AstraZeneca in a research note on Wednesday. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a £145 price objective on shares of AstraZeneca in a research report on Tuesday, September 8th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a £117 target price on shares of AstraZeneca in a research note on Tuesday, September 29th. Finally, Citigroup boosted their target price on AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Six research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, AstraZeneca presently has an average rating of “Moderate Buy” and an average target price of £153.57.

AstraZeneca Trading Up 0.9%

Shares of LON:AZN opened at £119.98 on Wednesday. AstraZeneca has a 52-week low of £114.04 and a 52-week high of £157.32. The company has a debt-to-equity ratio of 64.10, a quick ratio of 0.59 and a current ratio of 0.89. The company has a market capitalization of £186.08 billion, a P/E ratio of 17.96, a price-to-earnings-growth ratio of 0.86 and a beta of 0.20. The company has a 50-day simple moving average of £120.45 and a 200 day simple moving average of £131.98.

Insider Buying and Selling at AstraZeneca

In other news, insider Michel Demare purchased 2,500 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The stock was acquired at an average cost of £121.21 per share, with a total value of £303,025. Company insiders own 0.15% of the company’s stock.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.